Ophthalmology Innovation Summit

What Ophthalmology Innovation Summit does

Ophthalmology Innovation Summit (OIS), founded in 2009 and based in Jericho, New York, organizes curated in-person conferences and media products that convene stakeholders in the ophthalmology innovation ecosystem. Its events include the flagship summit series (OIS XV held in November 2025, with OIS XVI scheduled for March 2027), OIS Retina (July 2026), and OIS Ignite (March 2027), held at venues such as The Westin San Diego Gaslamp Quarter. These summits bring together four primary audiences: ophthalmology startups seeking visibility, venture capital and strategic investors sourcing deals, large pharmaceutical/biotech/medtech companies scouting partnerships and pipeline, and clinicians/key opinion leaders providing clinical input.

OIS operates a portfolio of three core product lines alongside its summits. The Eye on Innovation podcast (launched 2017) produces weekly interviews with industry executives, investors, KOLs, and researchers, with over 430 episodes published. The OIS Weekly newsletter distributes exclusive content, market updates, and event promotions via email. Sponsorship packages (Premier, Major, Supporting, Innovation, Media Partner tiers) provide corporate visibility and engagement opportunities, with OIS XV headlined by Bausch + Lomb as Premier Sponsor and Genentech and Lenz Therapeutics as Major Sponsors.

The business generates revenue through two primary streams: event registration (standard rate $1,399 per attendee, with a discounted $499 rate for practicing physicians) and corporate sponsorship. Distribution is direct via the ois.net website using Wufoo forms, with additional reach through YouTube, iTunes/Apple Podcasts, LinkedIn, and X (Twitter) (@OISTWEETS). OIS is structured as a privately held, founder-led company with 1-10 employees, no disclosed institutional investors or parent company, and no public financial reporting. Technology is described as an "event management and content production platform" with no proprietary software, patents, or AI-enabled features disclosed.

Name

Ophthalmology Innovation Summit

Legal name

Ophthalmology Innovation Summit

Website

https://ois.net

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Ophthalmology Innovation Summit organizes curated in-person summits (OIS XV, OIS Retina, OIS Ignite), the Eye on Innovation podcast, and OIS Weekly newsletter, serving ophthalmology startups, biotech and pharma strategics, venture investors, and clinician KOLs.

Ownership category

akta.pro rank

Product category

Healthcare Conferences / Medical Events

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Executive Summits & Invitation-Only Forums (MPAGAGAK)

Keywords

• Ophthalmology innovation events
• Medical device conferences
• Eye care summits
• Healthcare investor networking
• Biotech industry podcasts

Headquarters

HQ city

Jericho

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Event Registration: Registration fees for summits and conferences. Standard registration is $1399, with discounted rate of $499 for practicing physicians actively treating patients.
2. Sponsorship: Various sponsorship tiers including Premier Sponsor, Major Sponsor, Supporting Sponsor, Innovation Sponsor, and Media Partner. Sponsors include major ophthalmology companies like Bausch + Lomb, Genentech, and others.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Ophthalmology Innovation Summit (OIS) organizes and hosts curated in-person conferences that bring together ophthalmology startups, biotech and pharma strategics, investors, and clinicians to network, evaluate deal flow, and showcase breakthrough eye care technologies. Beyond flagship and specialized summits (OIS XV, OIS Retina, OIS Ignite), OIS produces the weekly Eye on Innovation podcast and the OIS Weekly newsletter, creating year-round community engagement around ophthalmic innovation.

Product overview

Ophthalmology Innovation Source (OIS) operates as an event and media organization rather than a technology product company. Its offerings consist of curated ophthalmology innovation summits (OIS XV, OIS Ignite, OIS Retina) that serve as a platform for networking among startups, investors, clinicians, and strategic partners. Additionally, OIS produces the Eye on Innovation podcast (OIS Podcast) featuring weekly interviews with industry leaders, and distributes an OIS Weekly newsletter. The portfolio is unified around community-building and knowledge-sharing in the ophthalmic innovation ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• Eye on Innovation Podcast: Weekly podcast featuring interviews with ophthalmology's most influential industry executives, investors, KOLs, and researchers
• OIS Retina
• OIS Ignite
• OIS Weekly

Products and services

• OIS Events/Summits Expertly curated multi-day in-person conferences bringing together ophthalmology startups, investors, strategics, and clinicians. Includes OIS XV (main flagship), OIS Retina (retinal innovation focused), and OIS Ignite. Sold to both individual attendees and corporate sponsors.
• OIS Podcast (Eye on Innovation) Weekly podcast featuring interviews with ophthalmology industry executives, investors, KOLs, and researchers discussing approaches to treating eye disease. Distributed via YouTube and Apple Podcasts to subscribers and listeners.
• OIS Weekly Newsletter Weekly email newsletter providing exclusive content, latest news, event updates, special promotions, and community updates to subscribers. Distributed via email subscription through ois.net.
• OIS Sponsorship Packages Multi-tier sponsorship opportunities (Premier Sponsor, Major Sponsor, Supporting Sponsor, Innovation Sponsor, Media Partner) for companies seeking visibility and engagement with the ophthalmic innovation community at OIS events.

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

18 partnerships are on record, tiered flagship, core, secondary and minor.

• Bausch + LombflagshipStrategic or Co-development Partner · 21 November 2025Premier Sponsor of OIS XV. Bausch + Lomb is a major ophthalmology company dedicated to protecting and enhancing sight, with comprehensive portfolio including contact lenses, eye care products, and surgical devices.
• GenentechcoreStrategic or Co-development Partner · 21 November 2025Major Sponsor of OIS XV. Genentech, a member of the Roche Group, researches and develops treatments for eye diseases including wet AMD, diabetic macular edema, diabetic retinopathy, and geographic atrophy.
• Lenz TherapeuticscoreStrategic or Co-development Partner · 21 November 2025Major Sponsor of OIS XV. Late-stage clinical company developing aceclidine-based eye drops for presbyopia restoration.
• Adverum BiotechnologiessecondaryStrategic or Co-development Partner · 21 November 2025Supporting Sponsor of OIS XV. Pioneering gene therapy for ocular diseases with lead program Ixoberogene soroparvovec (Ixo-vec) for wet AMD.
• Stuart TherapeuticssecondaryStrategic or Co-development Partner · 21 November 2025Supporting Sponsor of OIS XV. Clinical-stage drug platform developing PolyCol collagen mimetic peptide technology for ocular conditions including dry eye, corneal wound healing, and glaucoma.
• 4D Molecular TherapeuticssecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Late-stage biotech focused on genetic medicines for ophthalmology with lead program 4D-150 for wet AMD.
• ApellissecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Global biopharmaceutical company targeting complement system with Syfovre for geographic atrophy.
• Astellas PharmasecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Pharmaceutical company dedicated to improving health of people around the world through innovative pharmaceutical products.
• Cloudbreak PharmasecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Clinical-stage biotech developing ophthalmic drugs for chronic eye diseases with lead candidate CBT-001 for pterygium.
• Neurotech PharmaceuticalssecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Private biotech developing Encapsulated Cell Therapy for chronic eye diseases including MacTel.
• NovaliqsecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Biopharmaceutical company focusing on EyeSol water-free topical eyecare therapies including FDA-approved Miebo and Vevye for dry eye.
• Ocular TherapeutixsecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Biopharmaceutical company redefining retina experience with AXPAXLI for wet AMD in Phase 3 trials.
• OculissecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Global biopharmaceutical company developing OCS-01 for diabetic macular edema and neuroprotective candidate OCS-05.
• Ray TherapeuticssecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Bay Area biotech pioneering optogenetic therapy for vision restoration without need for light-enhancing goggles.
• REGENXBIOsecondaryStrategic or Co-development Partner · 21 November 2025Innovation Sponsor of OIS XV. Clinical-stage biotech advancing AAV Therapeutics for retinal and rare diseases including ABBV-RGX-314 for wet AMD.
• Collaborative Community on Ophthalmic Innovation (CCOI)coreStrategic or Co-development Partner · 21 November 2025CCOI presented a major session at OIS XV titled 'Innovating Together: Accelerating Solutions for Global Ophthalmic Challenges' covering topics like regulatory alignment, oculomics, and interoperability.
• ConexiantminorChannel Partner/ Reseller/ Distributor · 21 November 2025Media Partner for OIS XV.
• Powers & CominorChannel Partner/ Reseller/ Distributor · 21 November 2025Media Partner for OIS XV. Consulting firm specializing in commercialization and strategic marketing for life sciences.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• EBD Group (BIO-Europe / BIO-Europe Spring): Operates the largest biotech and pharma partnering conferences globally (BIO-Europe, BIO-Europe Spring, BioEquity). Same event-driven business model — registration fees, tiered sponsorships, curated networking — and same buyer personas (startups, VCs, strategics) as OIS, but in a broader biotech/pharma vertical rather than ophthalmology specifically.
• Demy-Colton Life Science Advisors: Runs boutique investor and CEO life sciences events (CEO Forum, Digital Medicine & Medtech, Biotech Showcase). Closely comparable GTM: curated invitation-only summits, sponsorship tiers, and year-round content aimed at life sciences startups, investors, and strategics — a near-identical template to OIS.
• Sachs Associates: Organizes invitation-only life sciences and healthcare investment conferences (e.g., European Life Sciences CEO Forum, Asia Biotech). Comparable for-profit, curated, sponsor-supported event model targeting the same audience profile as OIS, focused on biotech and specialty medicine rather than ophthalmology alone.

Broad incumbents

• American Academy of Ophthalmology (AAO): Hosts the largest annual ophthalmology meeting (AAO Annual Meeting) drawing the same KOLs, clinicians, and corporate sponsors as OIS. Competes for the same ophthalmology audience and sponsor dollars but operates as a professional membership association rather than a for-profit innovation summit organizer.
• Association for Research in Vision and Ophthalmology (ARVO): Runs the ARVO Annual Meeting, a major ophthalmology research congress that draws many of the same clinicians, researchers, and sponsors as OIS. Adjacent (research-leaning rather than commercial) but competes for the same ophthalmology mindshare and sponsor attention.
• ASCRS (American Society of Cataract and Refractive Surgery): Hosts the ASCRS Annual Meeting, a flagship ophthalmology subspecialty conference (cataract/refractive). Competes with OIS Retina and OIS Ignite for ophthalmic surgeon attendance and corporate sponsorships, with deeper subspecialty depth in anterior segment.
• BIO (Biotechnology Innovation Organization): Runs the BIO International Convention, the world's largest biotech partnering event. Overlaps with OIS in the startup-investor-strategic deal-making model and competes for the same ophthalmology sponsor and attendee pool, though at vastly broader scale.
• LSX (formerly Life Science Xchange) / Informa Connect: Operates specialty life sciences investor and partnering events (e.g., LSX USA Congress, Medtech & Pharma Platform). Closely analogous curated, sponsor-driven conference model for healthtech and biotech dealmakers, backed by a much larger media group.

Emerging players

• Glaucoma Research Foundation – Glaucoma 360: Annual Glaucoma 360 fundraising and innovation event uniting ophthalmology startups, clinicians, and corporate partners. Comparable thematic (specialty ophthalmology innovation forum) but narrower therapeutic focus and operated by a nonprofit rather than a for-profit media business.

Regional players

• Healio (Ophthalmology): Publishes ophthalmology news, hosts CME and specialty events, and runs ophthalmology-focused content and webinars. Competes for ophthalmologist mindshare and ophthalmic advertiser dollars, complementing rather than directly matching OIS's premium in-person summit focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/OISTWEETS
• YouTubeyoutube.com/c/OphthalmologySummit
• LinkedInlinkedin.com/company/2189664

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ophthalmology Innovation Summit